Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nephrourol Mon. 2014 Jan 14;6(1):e12148. doi: 10.5812/numonthly.12148. eCollection 2014.

Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan.

Author information

  • 1Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran ; Molecular and Cellular Biology Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • 2Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • 3Molecular and Cellular Biology Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.
  • 4Mazandaran University of Medical Sciences, Sari, IR Iran.
  • 5Department of Biostatistics and Epidemiology, Mazandaran University of Medical Sciences, Sari, IR Iran.

Abstract

BACKGROUND:

Diabetic nephropathy is the most important cause of end stage renal disease (ESRD). Aldosterone is involved in renal damage through induction of fibrosis, inflammation and necrosis in the kidney tissue. Previous studies have demonstrated that the combination of angiotensin receptor blocker (ARB) and spironolactone (an anti-aldosterone drug) are efficient for albuminuria reduction.

OBJECTIVES:

This study was designed to evaluate the effect of spironolactone alone on diabetic nephropathy.

PATIENTS AND METHODS:

In this double blind randomized clinical trial, 60 type II diabetic patients with microalbuminuria were enrolled. They were divided into two groups: case group (spironolactone 25 mg and placebo, 30 cases) and control (spironolactone 25 mg plus losartan 25 mg, 30 cases). The treatment success rate (more than 50% reduction in microalbuminuria) was compared between the two groups.

RESULTS:

After three months, successful treatment was seen in 70% (95% CI: 52 - 83) and 83.3% (CI 95%: 66 - 93) of case and control groups, respectively (P = 0.4). Mean ± SD of serum potassium levels after three months in case and control groups were 4.56 ± 0.38 and 4.39 ± 0.34 mEq/L, respectively (P = 0.08). Mean ± SD of systolic blood pressures in case and control groups were 129.67 ± 9.4 and 130.97 ± 9.4 mmHg, respectively (P = 0.6). Mean ± SD of serum creatinine levels at the end of the study were 0.95 ± 0.15 in case and 0.90 ± 0.22 mg/dL in control group (P = 0.4).

CONCLUSIONS:

Spironolactone alone is as effective as the combination of spironolactone and losartan on albuminuria reduction in type 2 diabetic patients and can be used alone as an effective drug for diabetic nephropathy.

KEYWORDS:

Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathy; Spironolactone

PMID:
24719811
[PubMed]
PMCID:
PMC3968951
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk